HRAS and neoplasm: To translate this result to a cancer context, the pTRF2 level was measured in different tumor cell lines with constitutive ERK1/2 activity (Cal33 cells overexpressing the EGF receptor, BJ-HELT RAS cells expressing H-RAS V12, A375 cells with B-RAFV600E mutation and U2OS cells overexpressing PDGF and IGFI/II receptors).